← Back to Screener
CNS Pharmaceuticals, Inc. Common Stock (CNSP)
Price$2.54
Favorite Metrics
Price vs S&P 500 (26W)-82.58%
Price vs S&P 500 (4W)1.42%
Market Capitalization$2.06M
All Metrics
Book Value / Share (Quarterly)$7.15
P/TBV (Annual)1.54x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-21.86
Price vs S&P 500 (YTD)-55.76%
EPS (TTM)$-40.81
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-40.81
EPS (Annual)$-35.75
ROI (Annual)-326.74%
Cash / Share (Quarterly)$11.38
ROA (Last FY)-183.81%
EBITD / Share (TTM)$-36.12
ROE (5Y Avg)-216.41%
Cash Flow / Share (Annual)$-21.86
P/B Ratio0.46x
P/B Ratio (Quarterly)0.72x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-1526.00x
ROA (TTM)-130.06%
EPS Incl Extra (Annual)$-35.75
Current Ratio (Annual)1.98x
Quick Ratio (Quarterly)1.77x
3-Month Avg Trading Volume0.04M
52-Week Price Return-74.19%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.41
52-Week High$34.80
EPS Excl Extra (Annual)$-35.75
CapEx CAGR (5Y)-1.89%
26-Week Price Return-73.83%
Quick Ratio (Annual)1.77x
13-Week Price Return-59.03%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)1.98x
Enterprise Value$-4.811
Book Value / Share Growth (5Y)-12.35%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.38
3-Month Return Std Dev93.21%
Net Income / Employee (TTM)$-4
ROE (Last FY)-350.48%
Net Interest Coverage (Annual)-968.35x
EPS Basic Excl Extra (Annual)$-35.75
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-40.81
ROI (TTM)-161.66%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.03
Price vs S&P 500 (52W)-109.28%
Year-to-Date Return-51.62%
5-Day Price Return1.20%
EPS Normalized (Annual)$-35.75
ROA (5Y Avg)-349.09%
Month-to-Date Return6.28%
Cash Flow / Share (TTM)$-6.63
EBITD / Share (Annual)$-36.05
ROI (5Y Avg)-204.23%
EPS Basic Excl Extra (TTM)$-40.81
P/B Ratio (Annual)0.72x
Book Value / Share (Annual)$7.15
Price vs S&P 500 (13W)-61.90%
Beta0.64x
Revenue / Share (TTM)$0.00
ROE (TTM)-164.56%
52-Week Low$2.06
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CNSPCNS Pharmaceuticals, Inc. Common Stock | — | — | — | — | $2.54 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
CNS Pharmaceuticals is a clinical-stage biopharmaceutical company developing anticancer therapies for brain and central nervous system tumors. The company's lead candidate, Berubicin, is in development for glioblastoma, an aggressive form of primary brain cancer with limited treatment options. The company aims to address significant unmet medical needs in oncology.